milnacipran has been researched along with Depression, Involutional in 89 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.25) | 18.2507 |
| 2000's | 37 (41.57) | 29.6817 |
| 2010's | 48 (53.93) | 24.3611 |
| 2020's | 2 (2.25) | 2.80 |
| Authors | Studies |
|---|---|
| Ikenouchi, A; Okamoto, N; Yoshimura, R | 1 |
| Bhatia, MS; Ghosh, R; Gupta, LK; Gupta, R; Tripathi, AK | 1 |
| Abdool, PS; Mulsant, BH; Patel, K; Rajji, TK | 1 |
| Ohmura, Y; Tsutsui-Kimura, I; Yoshida, T; Yoshioka, M | 1 |
| An, X; Fan, Y; Guo, L; He, H; Lyu, J; Ma, X; Wang, W; Zheng, J | 1 |
| Ho, PT; McIntyre, RS; Ragguett, RM; Yim, SJ | 1 |
| Gartlehner, G; Klerings, I; Schultes, MT; Teufer, B; Titscher, V; Wagner, G | 1 |
| Copolov, DL; Hope, J; Keks, NA; Keogh, S | 1 |
| Asnis, GM; Bose, A; Chen, C; Gommoll, CP; Greenberg, WM | 1 |
| Bose, A; Li, D; Li, H; Mansuy, L; Montgomery, SA; Ruth, A | 1 |
| Chen, C; Forero, G; Gommoll, C; Greenberg, WM; Mago, R | 1 |
| Cameron, F; Garnock-Jones, KP; Hair, P | 1 |
| Citrome, L | 2 |
| Bakish, D; Bose, A; Chen, C; Gommoll, C; Greenberg, WM; Khan, A; Liebowitz, M; Nunez, R | 1 |
| Gommoll, C; Li, D; Mansuy, L; Montgomery, SA; Ruth, AC | 1 |
| Bose, A; Chen, C; Gommoll, CP; Greenberg, WM; Sambunaris, A; Sheehan, DV | 1 |
| Gandhi, MA; Saraceni, MM; Venci, JV | 1 |
| Mago, R; Mahajan, R; Thase, ME | 1 |
| Chen, C; Gommoll, C; Greenberg, WM; Sambunaris, A | 1 |
| Kaneko, K; Matsumura, H; Nakagome, K; Ohta, Y; Pu, S; Terachi, S; Yamada, T; Yamanashi, T; Yokoyama, K | 1 |
| Chen, C; Gommoll, CP; Greenberg, WM; Montgomery, SA | 1 |
| Deardorff, WJ; Grossberg, GT | 1 |
| Chang, YH; Chen, PS; Chen, SH; Chen, SL; Cheng, LY; Chu, CH; Chuang, HY; Lee, IH; Lu, RB; Wang, YS; Yang, YK; Yeh, TL | 1 |
| Blum, SI; Ruth, A; Tourkodimitris, S | 1 |
| Scott, LJ | 1 |
| Biswas, D; Hameed, N; Khan, M; Rizvi, SM; Shaikh, S; Shakil, S | 1 |
| Higuchi, H; Inoue, K; Ishigooka, J; Kamata, M; Suzuki, T; Takahashi, H; Yoshida, K | 1 |
| Roman, MW; Wilkinson, SM | 1 |
| Azuma, J; Kato, M; Kinoshita, T; Nonen, S; Serretti, A; Takekita, Y; Wakeno, M | 1 |
| Chen, L; Ghahramani, P; Gommoll, C; Greenberg, WM; O'Connor, J; Periclou, A; Zukin, SR | 1 |
| McLaughlin, MR; Zaman, S | 1 |
| Bruno, A; Morabito, P; Muscatello, MR; Spina, E | 1 |
| Chen, C; Fava, M; Freeman, MP; Gommoll, C; Greenberg, WM; Ruth, A | 1 |
| Chen, C; Gommoll, C; Kornstein, SG; Kramer, K | 1 |
| Asnis, GM; Caneva, E; Henderson, MA | 1 |
| Bai, SJ; Huang, T; Lan, XH; Qin, B; Xie, P; Xu, Y | 1 |
| Chen, C; Gommoll, C; McIntyre, RS; Ruth, A | 1 |
| Hozumi, S; Sekine, A; Shimizu, T | 1 |
| Chen, C; Gommoll, C; Kramer, K; Sambunaris, A; Thase, ME | 1 |
| Chen, C; Gommoll, C; Harvey, PD; McIntyre, RS; Sambunaris, A; Wesnes, KA | 1 |
| Blier, P; Chen, C; Gommoll, C; Kramer, K | 1 |
| Iga, JI; Nakata, S; Ochi, S; Ueno, SI; Yamazaki, K; Yoshino, Y | 1 |
| Baldwin, D; Briley, M; Moreno, RA | 1 |
| Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; McGuire, H; Nakagawa, A; Omori, IM; Watanabe, N | 2 |
| Azuma, J; Fukuda, T; Hosoi, Y; Kato, M; Kinoshita, T; Nonen, S; Okugawa, G; Takekita, Y; Wakeno, M; Yamashita, M | 1 |
| Asada, T; Hatanaka, K; Mizukami, K; Sato, S; Tanaka, Y | 1 |
| Chang, TT; Chen, YC; Lee, SY; Lêng, CH; Lu, RB; Wang, YS; Wu, JY | 1 |
| Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R | 1 |
| Gourion, D; Montagne, A; Olié, JP; Poirier, MF; Rostin, M | 1 |
| Bitter, I; Karamustafalioglu, O; Koponen, H; Mohr, P; Sartorius, N; Seifritz, E; Svestka, J | 1 |
| Higuchi, H | 1 |
| Aggarwal, A; Jiloha, RC; Khandelwal, A | 1 |
| Boku, S; Honma, H; Inoue, T; Koyama, T; Nakagawa, S | 1 |
| Arora, G; Goyal, R | 1 |
| Azuma, J; Hasegawa, R; Hiratsuka, K; Ishiwata, K; Kato, M; Kinoshita, T; Kurosawa, T; Kurose, K; Nishikawa, J; Nonen, S; Okugawa, G; Saito, Y; Wakeno, M | 1 |
| Arakawa, R; Fujiwara, H; Fukuda, H; Ichimiya, T; Ito, H; Kimura, Y; Kodaka, F; Mori, T; Nagashima, T; Nogami, T; Okubo, Y; Sasaki, T; Sekine, M; Shimada, H; Suhara, T; Suzuki, M; Takahashi, H; Takahata, K; Takano, H; Tateno, A | 1 |
| Ferrey, G; Tournoux, A; Van Amerongen, AP | 1 |
| Higuchi, H; Ito, K; Kamata, M; Naito, S; Sato, K; Shimizu, T; Takahashi, H; Tsukamoto, K; Yoshida, K | 1 |
| Higuchi, H; Shimizu, T; Takahashi, H; Yoshida, K | 1 |
| Arita, S; Morishita, S | 3 |
| Burrows, GD; Gupta, RK; Tiller, JW | 1 |
| Higuchi, H; Hishikawa, Y; Ito, K; Kamata, M; Naito, S; Nakanishi, M; Sato, K; Shimizu, T; Takahashi, H; Tsukamoto, K; Yoshida, K | 1 |
| Kawai, M; Minabe, Y; Mori, N; Sekine, Y; Suzuki, K; Takei, N; Tani, K; Toyoda, T | 1 |
| Conesa, A; Lopez-Ibor, JJ | 1 |
| Higuchi, H; Sato, K; Shimizu, T; Takahashi, H; Watanabe, J; Yoshida, K | 1 |
| Preskorn, SH | 2 |
| Inada, E; Kanemoto, K; Matsubara, M; Sekine, T; Tarao, Y; Yamashita, K | 1 |
| Cabanac, F; Pezous, N; Sechter, D; Tournoux, A; Vandel, P; Weiller, E | 1 |
| Kobayashi, N; Nomura, S; Sawamura, T; Yoshida, T; Yoshino, A | 1 |
| Almási, J; Rihmer, Z | 1 |
| Briley, M; Grady, MM; Moret, C; Stahl, SM | 1 |
| Chee, IS; Choe, BM; Ham, BJ; Jung, HY; Kee, BS; Kim, JB; Lee, C; Lee, MS; Oh, BH; Oh, KS; Paik, IH; Yeon, BK | 1 |
| Fava, M; Papakostas, GI | 1 |
| Asada, T; Ohta, H; Sato, S; Terashima, Y; Yamakawa, Y | 1 |
| Furukawa, TA; Okumura, K | 1 |
| de Toledo Ferraz Alves, TC; Guerra de Andrade, A | 1 |
| Higuchi, H; Ito, K; Kamata, M; Naito, S; Ohkubo, T; Sato, K; Shimizu, T; Takahashi, H; Yoshida, K | 1 |
| Nomura, S; Sato, Y; Shigemura, J; Yoshino, A | 1 |
| Higuchi, H; Inoue, K; Itoh, K; Kamata, M; Ozaki, N; Sato, K; Suzuki, T; Takahashi, H; Yoshida, K | 1 |
| Higuchi, H; Kamata, M; Otani, K; Sato, K; Takahashi, H; Yamaguchi, N; Yoshida, K | 1 |
| Chartres, JP; Léger, JM; Pezous, N; Plétan, Y; Pujol-Domenech, J; Tignol, J; Tonelli, I; Tournoux, A | 1 |
| Berdeaux, G; Dardennes, R; Fagnani, F; Lafuma, A | 1 |
| Clerc, G | 1 |
| Ishigooka, J | 1 |
24 review(s) available for milnacipran and Depression, Involutional
| Article | Year |
|---|---|
Pharmacotherapy of major depression in late life: what is the role of new agents?
Topics: Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Humans; Milnacipran; Piperazines; Randomized Controlled Trials as Topic; Sulfides; Vilazodone Hydrochloride; Vortioxetine | 2017 |
Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
Topics: Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Humans; Milnacipran; Piperazines; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sulfides; Vilazodone Hydrochloride; Vortioxetine | 2018 |
Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclopropanes; Depressive Disorder, Major; Humans; Milnacipran; Network Meta-Analysis; Piperazines; Sulfides; Vilazodone Hydrochloride; Vortioxetine | 2018 |
Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant.
Topics: Depressive Disorder, Major; Fibromyalgia; Humans; Milnacipran; Serotonin and Noradrenaline Reuptake Inhibitors | 2018 |
Levomilnacipran extended release: first global approval.
Topics: Antidepressive Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Humans; Milnacipran; Randomized Controlled Trials as Topic | 2013 |
Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Topics: Antidepressive Agents; Capsules; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Humans; Milnacipran; Numbers Needed To Treat; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2013 |
Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Drug Administration Schedule; Humans; Milnacipran; Selective Serotonin Reuptake Inhibitors | 2014 |
Levomilnacipran: a newly approved drug for treatment of major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Clinical Trials as Topic; Cyclopropanes; Depressive Disorder, Major; Humans; Milnacipran; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Time Factors | 2014 |
A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
Topics: Antidepressive Agents; Benzofurans; Clinical Trials, Phase III as Topic; Cyclopropanes; Depressive Disorder, Major; Humans; Indoles; Milnacipran; Piperazines; Sulfides; Vilazodone Hydrochloride; Vortioxetine | 2014 |
Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Drug Utilization Review; Humans; Milnacipran; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult | 2014 |
Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary.
Topics: Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Drug Approval; Humans; Milnacipran; Piperazines; Sulfides; United States; United States Food and Drug Administration; Vortioxetine | 2014 |
The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.
Topics: Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Female; Humans; Male; Milnacipran; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2016 |
A review of antidepressant-induced urinary hesitancy: a focus on levomilnacipran ER including two case presentations(5633).
Topics: Antidepressive Agents; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Humans; Male; Middle Aged; Milnacipran; Quality of Life; Urination Disorders | 2016 |
Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability.
Topics: Adolescent; Antidepressive Agents; Child; Cyclopropanes; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Humans; Male; Milnacipran; Placebos; Randomized Controlled Trials as Topic; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis.
Topics: Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Drug Evaluation; Humans; Meta-Analysis as Topic; Milnacipran; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic | 2008 |
Milnacipran versus other antidepressive agents for depression.
Topics: Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Humans; Milnacipran; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2009 |
[Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].
Topics: Adult; Aged; Alleles; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Fluvoxamine; Forecasting; Humans; Male; Middle Aged; Milnacipran; Norepinephrine Plasma Membrane Transport Proteins; Pharmacogenetics; Polymorphism, Genetic; Promoter Regions, Genetic; Racial Groups; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Young Adult | 2010 |
Dual action antidepressants and some important considerations.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Second-Generation; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Histamine H1 Antagonists; Humans; Mianserin; Milnacipran; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Venlafaxine Hydrochloride; Weight Gain | 2003 |
Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor.
Topics: Animals; Cyclopropanes; Depressive Disorder, Major; Humans; Infusion Pumps, Implantable; Milnacipran; Norepinephrine; Rats; Selective Serotonin Reuptake Inhibitors | 2004 |
Reboxetine: a norepinephrine selective reuptake pump inhibitor.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Biological Availability; Clinical Trials as Topic; Cyclopropanes; Depressive Disorder, Major; Drug Approval; Duloxetine Hydrochloride; Humans; Metabolic Clearance Rate; Milnacipran; Morpholines; Reboxetine; Thiazepines; Thiophenes; United States | 2004 |
[Review of antidepressants from the TCAs to the third generation drugs].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Drug Combinations; Duloxetine Hydrochloride; Humans; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Morpholines; Piperazines; Pyrimidines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Trazodone; Triazoles; Venlafaxine Hydrochloride | 2004 |
SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.
Topics: Antidepressive Agents; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; In Vitro Techniques; Milnacipran; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Venlafaxine Hydrochloride; Vesicular Monoamine Transport Proteins | 2005 |
A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
Topics: Antidepressive Agents; Confidence Intervals; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Milnacipran; Odds Ratio; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
[Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Clinical Trials as Topic; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Humans; Milnacipran; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2001 |
34 trial(s) available for milnacipran and Depression, Involutional
| Article | Year |
|---|---|
Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
Topics: Adult; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Humans; Male; Middle Aged; Milnacipran; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Stereoisomerism; Treatment Outcome | 2013 |
Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Severity of Illness Index; Treatment Outcome; Young Adult | 2013 |
Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.
Topics: Adult; Antidepressive Agents; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Tachycardia; Time Factors | 2013 |
Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult | 2014 |
The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult | 2014 |
A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Chemistry, Pharmaceutical; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Least-Squares Analysis; Logistic Models; Male; Middle Aged; Milnacipran; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; United States | 2014 |
Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Humans; Male; Middle Aged; Milnacipran; Psychiatric Status Rating Scales; Remission Induction; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Young Adult | 2014 |
Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Treatment Outcome; Young Adult | 2015 |
Venlafaxine, paroxetine and milnacipran for major depressive disorder: a pragmatic 24-week study.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Health Status; Humans; Male; Mental Health; Middle Aged; Milnacipran; Prospective Studies; Psychiatric Status Rating Scales; Social Behavior; Treatment Outcome; Young Adult | 2015 |
Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.
Topics: Age Factors; Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclopropanes; Depressive Disorder, Major; Female; Fibroblast Growth Factors; Fluvoxamine; Humans; Japan; Male; Middle Aged; Milnacipran; Paroxetine; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT1A; Receptors, Adrenergic, alpha-2; Serotonin Plasma Membrane Transport Proteins; Sex Factors; Treatment Outcome | 2015 |
Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition.
Topics: Adult; Area Under Curve; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Healthy Volunteers; Humans; Male; Milnacipran; Norepinephrine Plasma Membrane Transport Proteins; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins | 2015 |
The effects of levomilnacipran ER in adult patients with first-episode, highly recurrent, or chronic MDD.
Topics: Adult; Antidepressive Agents; Chronic Disease; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Recurrence; Treatment Outcome | 2016 |
Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.
Topics: Adult; Antidepressive Agents; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Motivation; Psychiatric Status Rating Scales; Recovery of Function; Treatment Outcome | 2016 |
Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study.
Topics: Adult; Antidepressive Agents; Cognitive Dysfunction; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Treatment Outcome | 2017 |
Resolution of sexual dysfunction during acute treatment of major depression with milnacipran.
Topics: Adult; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Sexual Dysfunctions, Psychological; Surveys and Questionnaires | 2008 |
The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Alleles; Antidepressive Agents; Asian People; Cyclopropanes; Depressive Disorder, Major; Female; Gene Expression Regulation; Humans; Japan; Male; Middle Aged; Milnacipran; Paroxetine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptors, Adrenergic, alpha-2; Time Factors | 2008 |
Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan.
Topics: Adolescent; Adult; Aged; Asian People; Cyclopropanes; Depressive Disorder, Major; Follow-Up Studies; Humans; Middle Aged; Milnacipran; Molecular Structure; Paroxetine; Taiwan | 2008 |
Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine.
Topics: Adult; Aged; Antidepressive Agents; Blood Platelets; Case-Control Studies; Cyclopropanes; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Male; Middle Aged; Milnacipran; Nitric Oxide; Paroxetine; Statistics as Topic; Time Factors | 2009 |
[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; France; Humans; Male; Middle Aged; Milnacipran; Personality Inventory; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide Prevention; Venlafaxine Hydrochloride; Young Adult | 2009 |
A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression.
Topics: Adult; Aged; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; Drug Tolerance; Female; Follow-Up Studies; Humans; Imipramine; Male; Middle Aged; Milnacipran | 2002 |
Remarkable effect of milnacipran in the treatment of Japanese major depressive patients.
Topics: Adrenergic Uptake Inhibitors; Cyclopropanes; Depressive Disorder, Major; Female; Humans; Japan; Male; Middle Aged; Milnacipran; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2002 |
The clinical use of milnacipran for depression.
Topics: Adult; Age Factors; Antidepressive Agents; Bipolar Disorder; Cyclopropanes; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Milnacipran; Psychiatric Status Rating Scales; Random Allocation; Time Factors; Treatment Outcome | 2003 |
Milnacipran plasma levels and antidepressant response in Japanese major depressive patients.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Chromatography, High Pressure Liquid; Cyclopropanes; Depressive Disorder, Major; Female; Humans; Linear Models; Male; Middle Aged; Milnacipran; Selective Serotonin Reuptake Inhibitors | 2003 |
A comparative study of milnacipran and imipramine in the treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Imipramine; Male; Middle Aged; Milnacipran; Treatment Outcome | 2004 |
Controlled comparison of two different doses of milnacipran in major depressive outpatients.
Topics: Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Milnacipran; Outpatients; Psychiatric Status Rating Scales; Treatment Outcome | 2004 |
A comparative study of milnacipran and paroxetine in outpatients with major depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Ambulatory Care; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Psychomotor Disorders; Reaction Time; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
Topics: Adult; Aged; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Female; Fluoxetine; Humans; Korea; Male; Middle Aged; Milnacipran; Safety; Treatment Outcome | 2005 |
A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
Topics: Antidepressive Agents; Confidence Intervals; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Milnacipran; Odds Ratio; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Efficacy of milnacipran on cognitive dysfunction with post-stroke depression: preliminary open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Cognition Disorders; Cyclopropanes; Depressive Disorder; Depressive Disorder, Major; Female; Functional Laterality; Humans; Male; Middle Aged; Milnacipran; Mood Disorders; Psychiatric Status Rating Scales; Stroke; Tomography, X-Ray Computed | 2006 |
Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Alleles; Antidepressive Agents; Asian People; Catechol O-Methyltransferase; Cyclopropanes; Depressive Disorder, Major; Female; Genotype; Humans; Japan; Male; Middle Aged; Milnacipran; Polymerase Chain Reaction; Polymorphism, Genetic; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Tyrosine 3-Monooxygenase | 2008 |
Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.
Topics: Adrenergic Uptake Inhibitors; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclopropanes; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imipramine; Male; Milnacipran; Personality Inventory; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1998 |
Comparison of the cost-effectiveness of milnacipran (a SNRI) with TCAs and SSRIs: a modeling approach.
Topics: Adrenergic Antagonists; Adult; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Cyclopropanes; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Female; Follow-Up Studies; Humans; Male; Milnacipran; Models, Econometric; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity | 1999 |
Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
Topics: Adult; Aged; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Treatment Outcome | 2001 |
32 other study(ies) available for milnacipran and Depression, Involutional
| Article | Year |
|---|---|
Effect of Milnacipran on Plasma Level of Vascular Endothelial Growth Factor in Major Depression.
Topics: Antidepressive Agents; Cyclopropanes; Depression; Depressive Disorder, Major; Humans; Milnacipran; Selective Serotonin Reuptake Inhibitors; Vascular Endothelial Growth Factor A | 2022 |
Effect of milnacipran on brain‑derived neurotrophic factor and oxidative stress biomarkers in patients of major depressive disorder.
Topics: Antidepressive Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Humans; Milnacipran; Selective Serotonin Reuptake Inhibitors | 2023 |
Milnacipran affects mouse impulsive, aggressive, and depressive-like behaviors in a distinct dose-dependent manner.
Topics: Aggression; Animals; Behavior, Animal; Cyclopropanes; Depressive Disorder, Major; Dopamine; Dose-Response Relationship, Drug; Impulsive Behavior; Injections, Intraperitoneal; Male; Mice, Inbred C57BL; Milnacipran; Prefrontal Cortex; Selective Serotonin Reuptake Inhibitors; Serotonin | 2017 |
Efficacy of levomilnacipran extended release in treating major depressive disorder.
Topics: Antidepressive Agents; Clinical Trials as Topic; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Drug Interactions; Half-Life; Humans; Milnacipran; Serotonin and Noradrenaline Reuptake Inhibitors | 2017 |
Milnacipran influences the indexes of I-metaiodobenzylguanidine scintigraphy in elderly depressed patients.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Antidepressive Agents; Brain; Cyclopropanes; Depressive Disorder, Major; Diagnosis, Differential; Female; Humans; Lewy Body Disease; Male; Milnacipran; Radionuclide Imaging; Radiopharmaceuticals | 2014 |
Fetzima (levomilnacipran), a drug for major depressive disorder as a dual inhibitor for human serotonin transporters and beta-site amyloid precursor protein cleaving enzyme-1.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Antidepressive Agents; Aspartic Acid Endopeptidases; Cyclopropanes; Depressive Disorder, Major; Humans; Milnacipran; Molecular Docking Simulation; Serotonin Plasma Membrane Transport Proteins | 2014 |
Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
Topics: Antidepressive Agents; Asian People; Cyclin D1; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Genotype; Humans; Male; Middle Aged; Milnacipran; Polymorphism, Single Nucleotide; Receptors, Glucocorticoid; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2014 |
Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out.
Topics: Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Humans; Milnacipran; Piperazines; Sulfides; Vilazodone Hydrochloride; Vortioxetine | 2015 |
Levomilnacipran (Fetzima) for Major Depressive Disorder.
Topics: Adult; Antidepressive Agents; Cardiovascular System; Cyclopropanes; Depressive Disorder, Major; Dose-Response Relationship, Drug; Humans; Milnacipran; Psychiatric Status Rating Scales; Psychological Techniques; Serotonin Syndrome; Suicidal Ideation; Suicide; Suicide Prevention; Treatment Outcome | 2015 |
Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.
Topics: Activities of Daily Living; Adult; Antidepressive Agents; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Fatigue; Female; Humans; Male; Middle Aged; Milnacipran; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome | 2016 |
The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.
Topics: Adult; Anhedonia; Anorexia; Antidepressive Agents; Clinical Trials, Phase III as Topic; Cyclopropanes; Delayed-Action Preparations; Depression; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Randomized Controlled Trials as Topic; Suicidal Ideation; Treatment Outcome | 2016 |
Influence of painful physical symptoms in the treatment of Japanese patients with melancholic major depressive disorder: A prospective cohort study.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Comorbidity; Cyclopropanes; Depressive Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Milnacipran; Pain; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome | 2016 |
Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Anxiety; Cluster Analysis; Cyclopropanes; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Fatigue; Female; Humans; Male; Middle Aged; Milnacipran; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2017 |
Endothelial nitric oxide synthase in rat brain is downregulated by sub-chronic antidepressant treatment.
Topics: Animals; Antidepressive Agents; Brain; Cyclopropanes; Depressive Disorder, Major; Down-Regulation; Drug Administration Schedule; Male; Mianserin; Milnacipran; Mirtazapine; Nitric Oxide; Nitric Oxide Synthase Type III; Rats; Rats, Wistar; RNA, Messenger | 2017 |
Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease.
Topics: Adrenergic Uptake Inhibitors; Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Milnacipran; Nootropic Agents; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors | 2009 |
Management of depression in the presence of pain symptoms.
Topics: Antidepressive Agents; Brain; Chronic Disease; Clinical Trials as Topic; Combined Modality Therapy; Comorbidity; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Fibromyalgia; Humans; Milnacipran; Mind-Body Relations, Metaphysical; Norepinephrine; Pain; Psychotherapy; Serotonin; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Milnacipran-associated urinary retention: a case report.
Topics: Adult; Cyclopropanes; Depressive Disorder, Major; Follow-Up Studies; Humans; Male; Milnacipran; Sertraline; Urinary Retention | 2010 |
Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study.
Topics: Adolescent; Adult; Aged; Benzodiazepines; Cyclopropanes; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Milnacipran; Olanzapine; Young Adult | 2011 |
Sexual side effects of milnacipran.
Topics: Adult; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Humans; Male; Milnacipran; Sexual Dysfunction, Physiological | 2011 |
Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Asian People; Cohort Studies; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Genome-Wide Association Study; Genotype; GPI-Linked Proteins; Humans; Male; Middle Aged; Milnacipran; Neural Cell Adhesion Molecules; Paroxetine; Polymorphism, Single Nucleotide; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological | 2012 |
Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2).
Topics: Adult; Antidepressive Agents; Benzylamines; Brain; Brain Mapping; Carbon Radioisotopes; Cyclopropanes; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Fluorine Radioisotopes; Gas Chromatography-Mass Spectrometry; Humans; Male; Middle Aged; Milnacipran; Morpholines; Norepinephrine Plasma Membrane Transport Proteins; Positron-Emission Tomography; Protein Binding; Serotonin Plasma Membrane Transport Proteins | 2013 |
Elevation of blood pressure induced by high-dose milnacipran.
Topics: Adrenergic Uptake Inhibitors; Blood Pressure; Cyclopropanes; Depressive Disorder, Major; Humans; Hypertension; Male; Middle Aged; Milnacipran | 2002 |
Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
Topics: Antidepressive Agents; Bipolar Disorder; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Outpatients; Paroxetine; Psychiatric Status Rating Scales; Retrospective Studies; Time Factors; Treatment Outcome | 2003 |
Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Cohort Studies; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Personality Inventory; Psychometrics; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sex Factors; Treatment Outcome | 2003 |
Augmentation of milnacipran by risperidone in treatment for major depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Cyclopropanes; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Milnacipran; Psychiatric Status Rating Scales; Risperidone | 2004 |
Milnacipran treatment of a terminally ill cancer patient with major depressive disorder.
Topics: Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Humans; Lung Neoplasms; Male; Milnacipran; Terminal Care | 2004 |
The effectiveness of lithium augmentation of milnacipran: preliminary data using the modified Japanese Psychopharmacology Algorithm.
Topics: Adrenergic Uptake Inhibitors; Algorithms; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Drug Synergism; Female; Humans; Lithium; Male; Milnacipran; Selective Serotonin Reuptake Inhibitors | 2004 |
Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression.
Topics: Adult; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Milnacipran; Selective Serotonin Reuptake Inhibitors | 2006 |
Hypertension induced by regular doses of milnacipran: a case report.
Topics: Antidepressive Agents, Second-Generation; Blood Pressure; Cyclopropanes; Depressive Disorder, Major; Female; Humans; Hypertension; Middle Aged; Milnacipran | 2007 |
Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients.
Topics: Aging; Antidepressive Agents, Second-Generation; Cyclopropanes; Data Collection; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Japan; Male; Menopause; Middle Aged; Milnacipran; Psychiatric Status Rating Scales; Sex Characteristics | 2007 |
Patient satisfaction with antidepressants: an Internet-based study.
Topics: Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclopropanes; Data Collection; Depressive Disorder, Major; Fluvoxamine; Humans; Internet; Japan; Logistic Models; Milnacipran; Paroxetine; Patient Satisfaction; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires | 2008 |
No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders.
Topics: Adult; Affect; Aged; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Milnacipran; Personality Inventory; Prognosis; Treatment Outcome | 2008 |